ProBioGen and Saxonia BioTec to optimise new types of bioreactors for research and diagnostics
"ProBioGen - just great! The project management and company culture fit together perfectly, and we are securing unique know-how in the field of mammalian cell culture for our company," says Uwe Klaus, PhD, Managing Director of Saxonia BioTec. "The extensive mutual evaluation programme reflects the great synergies between both companies."
Uwe Marx, PhD, Chief Scientific Officer of ProBioGen AG: "I see a great potential for universal parallel cultivation of human micro-organ tissues in the innovative bioreactors designed by Saxonia BioTech. By using these reactors, we can stimulate relevant and meaningful drug screening tests while avoiding animal experiments at the same time."
Both companies will share the income from the various areas the technology is to be used in. Further financial details of the co-operation were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.